We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+8.62%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.71B
AUM Growth
+$201M
Cap. Flow
+$657M
Cap. Flow %
13.94%
Top 10 Hldgs %
37.6%
Holding
120
New
15
Increased
43
Reduced
17
Closed
23
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$135M
2
AZN icon
AstraZeneca
AZN
+$85.6M
3
BAX icon
Baxter International
BAX
+$72.7M
4
AVTR icon
Avantor
AVTR
+$60.9M
5
UNH icon
UnitedHealth
UNH
+$55.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$126M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$92.2M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$39.7M
4
EXAS icon
Exact Sciences
EXAS
+$35.2M
5
CMPS icon
Compass Pathways
CMPS
+$34.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.27%
2 Financials 0.5%
3 Technology 0.22%
4 Miscellaneous 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ABBV icon
1
AbbVie
ABBV
$504B
$269M 5.7%
1,985,000
+371,800
+23% +$43.9M
2019 Q4
8 quarters
ZNTL icon
2
Zentalis Pharmaceuticals
ZNTL
$210M
$228M 4.84%
2,715,000
+221,200
+9% +$17.1M
2020 Q2
6 quarters
ARVN icon
3
Arvinas
ARVN
$473M
$208M 4.4%
2,527,973
+293,273
+13% +$23.9M
2020 Q2
6 quarters
AVTR icon
4
Avantor
AVTR
$10.9B
$202M 4.28%
4,792,000
+1,544,300
+48% +$60.9M
2020 Q2
6 quarters
AZN icon
5
AstraZeneca
AZN
$258B
$167M 3.54%
1,433,600
+727,600
+103% +$85.6M
2021 Q3
1 quarter
BHVN icon
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$157M 3.33%
1,140,000
+205,800
+22% +$26.2M
2020 Q1
7 quarters
BAX icon
7
Baxter International
BAX
$13.4B
$152M 3.21%
1,765,000
+903,000
+105% +$72.7M
2021 Q3
1 quarter
ELV icon
8
Elevance Health
ELV
$92.7B
$149M 3.16%
+321,000
New +$135M
2021 Q4
0 quarters
PFE icon
9
Pfizer
PFE
$168B
$123M 2.62%
2,090,000
+1,063,200
+104% +$52.7M
2021 Q3
1 quarter
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$118M 2.51%
806,400
-256,000
-24% -$39.7M
2020 Q3
5 quarters
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$116M 2.47%
6,955,000
+2,855,000
+70% +$46.8M
2021 Q2
2 quarters
UTHR icon
12
United Therapeutics
UTHR
$23.1B
$116M 2.45%
535,000
+184,000
+52% +$36.1M
2021 Q2
2 quarters
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
$113M 2.4%
1,215,500
+76,500
+7% +$5.04M
2020 Q4
4 quarters
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$109M 2.31%
1,012,000
+186,000
+23% +$20.3M
2019 Q4
8 quarters
NBIX icon
15
Neurocrine Biosciences
NBIX
$14B
$107M 2.28%
1,260,000
+411,100
+48% +$37.8M
2020 Q4
4 quarters
BPMC icon
16
DELISTED
Blueprint Medicines
BPMC
$107M 2.26%
995,000
+163,000
+20% +$17.1M
2020 Q4
4 quarters
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
$106M 2.25%
685,000
+148,000
+28% +$24.8M
2021 Q1
3 quarters
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.2B
$106M 2.24%
4,823,400
– –
2020 Q2
6 quarters
LLY icon
19
Eli Lilly
LLY
$1.13T
$95.2M 2.02%
344,800
+14,800
+4% +$3.75M
2021 Q2
2 quarters
CTLT icon
20
DELISTED
CATALENT, INC.
CTLT
$89M 1.89%
695,000
+297,000
+75% +$38.2M
2020 Q3
5 quarters
NTRA icon
21
Natera
NTRA
$56.5B
$87.8M 1.86%
940,000
+301,300
+47% +$31.3M
2020 Q3
5 quarters
HOLX icon
22
DELISTED
Hologic
HOLX
$81.5M 1.73%
1,064,000
+118,600
+13% +$8.72M
2021 Q2
2 quarters
IOVA icon
23
Iovance Biotherapeutics
IOVA
$6.29B
$72.2M 1.53%
3,780,000
+2,317,800
+159% +$51M
2021 Q3
1 quarter
SHC icon
24
Sotera Health
SHC
$5.12B
$69.7M 1.48%
2,960,000
+582,000
+24% +$13.9M
2020 Q4
4 quarters
NUVB icon
25
Nuvation Bio
NUVB
$1.62B
$62.8M 1.33%
7,382,488
+119,000
+2% +$1.09M
2021 Q1
3 quarters
1
2 3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
FGA
Fortis Group Advisors Westwood, New Jersey $626M AUM 33.6% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $626M AUM 199.29% 1-Year Est. Return

Avidity Partners Management's Q4 2021 Portfolio in Review

As of Q4 2021, Avidity Partners Management held 120 positions worth $4.71B, up 4.5% from $4.51B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Avidity Partners Management deployed $657M of net new capital in Q4 2021, opening 15 new positions and adding to 43 existing holdings. Its largest new stake was Elevance Health: 321,000 shares worth $149M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 85% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $126M trimmed.

  • Avidity Partners Management's largest Q4 2021 buy was Elevance Health: 321,000 shares worth $149M.
  • Avidity Partners Management added most to AstraZeneca in Q4 2021, an estimated $85.6M increase.
  • Avidity Partners Management's biggest Q4 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $126M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q4 2021, selling an estimated $92.2M.
  • Avidity Partners Management's ten largest holdings make up 38% of its $4.71B portfolio in Q4 2021.
  • Avidity Partners Management opened 15 new positions and closed 23 in Q4 2021.
  • Avidity Partners Management's portfolio value rose 4.5% quarter-over-quarter to $4.71B.

Based on Avidity Partners Management's 13F filing for Q4 2021, filed 14 Feb 2022.